Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres ...

During the conference, authors of accepted abstracts will present in a lightning talk session. For abstract-reviewed presentations, submit an extended abstract (500-750 words in PDF (.pdf) file format ...

today announced that several abstracts highlighting the Company's innovative assets have been selected for presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting ...

today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR ...

Abstract Number for Publication: 7008 May 30, 20252:45 PM-5:45 PM CDT Oral Abstract Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Bispecific innate cell engager ...

today announced acceptance of abstract for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3, 2025, in Chicago ...

Pasithea Therapeutics Corp. has announced the acceptance of an abstract for a poster presentation at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 ...

In addition, two abstracts on AFM24 in combination with atezolizumab in non-small cell lung cancer (NSCLC) have been accepted as poster presentations. Details of the acimtamig oral presentation ...